drugset
drugset / Trial / NCT00077181

3-AP and High-Dose Cytarabine in Treating Patients With Advanced Hematologic Malignancies

NCT00077181 ↗

Phase 1 Completed 48 enrolled National Cancer Institute (NCI)
NaSingle-groupOpen-labelTreatment

Summary

Drugs used in chemotherapy, such as cytarabine, work in different ways to stop cancer cells from dividing so they stop growing or die. 3-AP may help cytarabine kill more cancer cells by making them more sensitive to the drug. This phase I trial is studying the side effects and best dose of 3-AP when given with high-dose cytarabine in treating patients with advanced hematologic malignancies

Timeline

Start
2004-01
Primary completion
2008-07
Completion
—

Drugs

EvaluationDrugModalityDoseRoute
Subject Triapine Small molecule — Intravenous
Background Cytarabine Small molecule — Intravenous

Indications

acute myeloid leukemia with 11q23 abnormalities acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) acute myeloid leukemia with t(8;21)(q22;q22) translocation acute myeloid leukemia, inv(16)(p13.1;q22) adult acute lymphoblastic leukemia blast phase chronic myelogenous leukemia, BCR-ABL1 positive leukemia, myeloid, accelerated-phase